From: Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
Outcome | Regression adjustment for all confounding factors OR (95%CI) | Regression adjustment for propensity score OR (95%CI) | Inverse probability weighting OR (95%CI) |
---|---|---|---|
Clinical relapse(s) | 3.43 (1.55, 7.60) | 2.84 (1.33, 6.06) | 2.34 (0.86, 6.72) |
New lesion on brain MRI | 4.40 (2.04, 9.50) | 4.30 (2.02, 9.14) | 3.77 (1.67, 8.99) |
New GD + lesion on brain MRI | 2.32 (0.87, 6.21) | 2.26 (0.84, 6.08) | 2.03 (0.67, 5.91) |
New T2 lesion on brain MRI | 4.89 (2.21, 10.85) | 4.98 (2.27, 10.91) | 4.11 (1.79, 10.04) |
Sustained disease progression | 1.32 (0.39, 4.42) | 1.09 (0.36, 3.32) | 0.92 (0.28, 2.44) |
No relapse, new MRI lesion or sustained progression (NEDA) | 0.27 (0.14, 0.50) | 0.30 (0.16, 0.56) | 0.35 (0.15, 0.75) |